씨엔알리서치

359090KOSDAQ그외 기타 전문, 과학 및 기술 서비스업

72.5 / 100

Reference Date: 2026-07-24

Financial Score27.5 / 40

News Sentiment20.0 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Operating Profit is on a declining trend. Surged 256.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

CNR Research, established in 1997 as Korea's first CRO, provides clinical trial services for drug development, including Phase I-III trials for regulatory approval and post-market studies (PMS/Phase IV). It maintains the top position among domestic CROs by revenue in 2023 and aims to expand globally through IT solution development and oncology trial expertise.

Number of Employees

522people

Average Salary

58.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

43.62Industry Average 42.303.0Point

Higher than industry avg (caution)

PBR

0.47Industry Average 1.087.0Point

Half of industry avg (excellent)

ROE

2.15Industry Average 0.947.0Point

2.3x industry avg (excellent)

Debt Ratio

5.27Industry Average 12.516.5Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲8.6% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼51.8% (2-year basis)

ROE Trend

2.0 / 4

Avg ROE 7.9% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
씨엔알리서치, EPSI 코리아 인수…“한·중·일 임상 플랫폼 확대”
씨엔알리서치의 EPSI Korea 인수로 아시아 임상 플랫폼 확장 및 시장 점유율 강화 기대.
Positive
씨엔알리서치, 시판 후 연구 전략 웨비나 개최…"RWD·RWE 활용 방...
씨엔알리서치가 시판 후 연구 웨비나 개최로 데이터 활용 능력 강화 및 시장 경쟁력 제고 기대.

Detailed Momentum

52-week position8.0Point

Near 52w high (99%, uptrend)

Current 1,963Won52-week high 1,97452-week low 511

1-month return6.0Point

1m +256.91% (strong rise)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주권매매거래정지해제 (액면병합 주권 변경상장)2026-06-29